RxDoctor Payments Data

Morgan Mankins

Family · Elgin, SCNPI 1417680422

Payments from drug & device makers

$869in general payments, 2019–2025

Across 16 payments — averaging $54.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$415
  • Cvrx, Inc.$136
  • Novo Nordisk$133
  • Idorsia Pharmaceuticals US Inc$112
  • Amgen$23
  • Pfizer$19
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$85799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$869 in reported general payments places this provider in the 60th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$28,652
Medicare patients
133
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$26,728
MounjaroTirzepatide16$20,842
FarxigaDapagliflozin Propanediol26$20,544
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$14,254
JardianceEmpagliflozin19$13,493
JanuviaSitagliptin Phosphate19$10,322
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$568
Albuterol Sulfate HfaAlbuterol Sulfate29$553
Omeprazole19$450
Levothyroxine Sodium37$418
Losartan Potassium34$398
Rosuvastatin Calcium41$375
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav39$340
Gabapentin34$334
Pantoprazole Sodium29$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$415$34,79848 claims
Novo NordiskOzempic$133$26,72813 claims
Lilly USA, LLCMounjaro$12$20,84216 claims
Boehringer IngelheimJardiance$19$13,49319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,248 family providers in South Carolina.

Other family in Elgin

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →